Use of anticoagulant drugs for hospitalised patients: A multicentre study
DOI:
https://doi.org/10.46542/pe.2024.243.286291Keywords:
Anticoagulant use, Inpatient, Multicentre studyAbstract
Background: Anticoagulants are indicated for several types of diseases with progression related to coagulation. Patients administered this drug need to be evaluated by the pharmacist regarding its effectiveness and possible side effects.
Objective: This research aimed to analyse the profile use of anticoagulants among patients at Yogyakarta Hospital.
Method: This research was a multicentre study conducted retrospectively using the medical records of inpatients who received anticoagulants.
Result: Among a total of 486 respondents, the majority were male (63.58%), and the adult age category (18-59 years) was 55.76%. Most anticoagulants were used in cases of cardiovascular disease, diagnosed with NSTEMI as much as 20.21%. The most used anticoagulant drug was heparin (48.9%), followed by fondaparinux (34.3%) and enoxaparin (16.8%). The most duration of anticoagulant use was one to four days (73.02%) with the dose range being 200-1000 units/day.
Conclusion: Heparin was the anticoagulant widely used in patients with NSTEMI. Although the elderly were the group most at risk of ADR due to anticoagulants, most of these drugs were precisely taken by adults, who also required serious attention. Further research is needed to provide a more comprehensive approach to anticoagulant therapy.
References
Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., Di Maio, A., Faggian, B., Franceschetti, M. E., Massari, M., Salvaggio, M., & Natalini, G. (2020). Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalised with SARS-CoV-2 infection. A cohort study. EClinicalMedicine, 27, 100562. https://doi.org/10.1016/j.eclinm.2020.100562
Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. E. (2021). Current trends in the duration of anticoagulant therapy for venous thromboembolism: A systematic review. Cureus, 13(10), e18992. https://doi.org/10.7759/cureus.18992
Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J. (2013). Anticoagulants: A review of the pharmacology, dosing, and complications. Current Emergency and Hospital Medicine Reports, 1(2), 83–97. https://doi.org/10.1007/s40138-013-0014-6
Antman, E. M., Cohen, M., McCabe, C., Goodman, S. G., Murphy, S. A., & Braunwald, E. (2002). Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. European Heart Journal, 23(4), 308–314. https://doi.org/10.1053/euhj.2001.2779
Bradbury, C. A., & McQuilten, Z. (2022). Anticoagulation in COVID-19. The Lancet, 399(10319), 5–7. https://doi.org/10.1016/S0140-6736(21)02503-4
DeWald, T. A., Washam, J. B., & Becker, R. C. (2018). Anticoagulants. Neurosurgery Clinics of North America, 29(4), 503–515. https://doi.org/10.1016/j.nec.2018.06.003
Ding, J., Sun, Y., Zhang, K., Huang, W., Tang, M., Zhang, D., & Xing, Y. (2024). Effects of anticoagulant therapy and frailty in the elderly patients with atrial fibrillation. Clinical Interventions in Aging, 19, 247–254. https://doi.org/10.2147/CIA.S453527
Douketis, J. D. (2022). Drugs for deep venous thrombosis—Cardiovascular disorders. MSD Manual Professional Edition. https://www.msdmanuals.com/professional/cardiovascular-disorders/peripheral-venous-disorders/drugs-for-deep-venous-thrombosisv
George, J., Rapsomaniki, E., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., Herrett, E., Smeeth, L., Timmis, A., & Hemingway, H. (2015). How does cardiovascular disease first present in women and men? Circulation, 132(14), 1320–1328. https://doi.org/10.1161/CIRCULATIONAHA.114.013797
Han, X., & Jin, L. (2020). Advances in the application of fondaparinux in acute coronary syndrome. Case Reports in Clinical Medicine, 9(7), Article 7. https://doi.org/10.4236/crcm.2020.97028
Kemenkes. (2022). Formularium Nasional.
Khan, M. Y., Ponde, C. K., Kumar, V., & Gaurav, K. (2022). Fondaparinux: A cornerstone drug in acute coronary syndromes. World Journal of Cardiology, 14(1), 40–53. https://doi.org/10.4330/wjc.v14.i1.40
Ko, D., Lin, K. J., Bessette, L. G., Lee, S. B., Walkey, A. J., Cheng, S., Kim, E., Glynn, R. J., & Kim, D. H. (2022). Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020. JAMA Network Open, 5(11), e2242964. https://doi.org/10.1001/jamanetworkopen.2022.42964
Larson, E. A., German, D. M., Shatzel, J., & DeLoughery, T. G. (2019). Anticoagulation in the cardiac patient: A concise review. European Journal of Haematology, 102(1), 3–19. https://doi.org/10.1111/ejh.13171v
Mukherjee, D. (2022). Heparin Use in acute coronary syndromes and cardiovascular interventions: Habit or evidence based. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2022/01/26/18/36/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2ften-points-to-remember%2f2022%2f01%2f26%2f18%2f36%2fHeparin-Use-in-Acute-Coronary-Syndromes
Onwordi, E. N., Gamal, A., & Zaman, A. (2018). Anticoagulant therapy for acute coronary syndromes. Interventional Cardiology Review, 13(2), 87–92. https://doi.org/10.15420/icr.2017:26:1
Rodriguez, F., & Harrington, R. A. (2021). Management of antithrombotic therapy after acute coronary syndromes. The New England Journal of Medicine, 384(5), 452–460. https://doi.org/10.1056/NEJMra1607714
Shah, S. J., Singer, D. E., Fang, M. C., Reynolds, K., Go, A. S., & Eckman, M. H. (2019). Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circulation: Cardiovascular Quality and Outcomes, 12(11), e006212. https://doi.org/10.1161/CIRCOUTCOMES.119.006212
Silvain, J., Beygui, F., Barthélémy, O., Pollack, C., Cohen, M., Zeymer, U., Huber, K., Goldstein, P., Cayla, G., Collet, J.-P., Vicaut, E., & Montalescot, G. (2012). Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: Systematic review and meta-analysis. BMJ, 344, e553. https://doi.org/10.1136/bmj.e553
Szummer, K., Oldgren, J., Lindhagen, L., Carrero, J. J., Evans, M., Spaak, J., Edfors, R., Jacobson, S. H., Andell, P., Wallentin, L., & Jernberg, T. (2015). Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non–ST-segment elevation myocardial infarction. JAMA, 313(7), 707–716. https://doi.org/10.1001/jama.2015.517
Tan, S., White, H. D., & Layland, J. (2022). Heparin use in acute coronary syndromes and cardiovascular interventions: Habit or evidence-based? European Heart Journal, 43(10), 1008–1011. https://doi.org/10.1093/eurheartj/ehab896
Tsigkas, G., Apostolos, A., Despotopoulos, S., Vasilagkos, G., Papageorgiou, A., Kallergis, E., Leventopoulos, G., Mplani, V., Koniari, I., Velissaris, D., & Parissis, J. (2021). Anticoagulation for atrial fibrillation in heart failure patients: Balancing between Scylla and Charybdis. Journal of Geriatric Cardiology: JGC, 18(5), 352–361. https://doi.org/10.11909/j.issn.1671-5411.2021.05.006v
Weerasaksanti, A., Siwamogsatham, S., Kunlamas, Y., & Bunditanukul, K. (2023). Factors associated with bleeding events from enoxaparin used for patients with acute coronary syndrome. BMC Cardiovascular Disorders, 23(1), 243. https://doi.org/10.1186/s12872-023-03278-9
World Health Organization. (2021). Guideline for the pharmacological treatment of hypertension in adults. World Health Organization. https://apps.who.int/iris/handle/10665/344424
Zeitler, E. P., & Eapen, Z. J. (2015). Anticoagulation in heart failure: A review. Journal of Atrial Fibrillation, 8(1), 1250. https://doi.org/10.4022/jafib.1250
